NBG 030
Alternative Names: NBG-030Latest Information Update: 25 Aug 2023
Price :
$50 *
At a glance
- Originator NB Health Laboratory
- Class Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Frizzled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Fibrosis
Most Recent Events
- 02 Jun 2023 NBG 030 is available for licensing as of 02 Jun 2023. https://nbhl.co.jp/partnering/ (NB Health Laboratory pipeline, June 2023)
- 01 Jun 2023 Early research in Cancer in Japan (Parenteral) (NB Health Laboratory pipeline, June 2023)
- 01 Jun 2023 Early research in Fibrosis in Japan (Parenteral) (NB Health Laboratory pipeline, June 2023)